- Celgene is in talks to acquire Juno Therapeutics,
- If the deal materializes, it'd be the second in 2018 for the biotech giant, which has been under pressure from investors.
- Juno is known for its experimental treatments that harness the body's immune system to treat cancer.
ADVERTISEMENT
Celgene is reportedly in talks to buy a $5.5 billion cancer drugmaker (JUNO, CELG)
If the deal materializes, it'd be the second in 2018 for the biotech giant, which has been under pressure from investors.
Biotech giant Celgene is in talks to buy cancer drugmaker Juno Therapeutics, The Wall Street Journal reports.
Celgene has been under pressure from investors to make some changes after a rocky 2017. Already in 2018, the company acquired$7 billion deal, a move that didn't entirely excite the biotech community.
Juno declined to comment on the report.
ADVERTISEMENT
Juno is developing a CAR T-cell therapy
Juno was up 40% Tuesday evening on the report.
JOIN OUR PULSE COMMUNITY!
ADVERTISEMENT
Eyewitness? Submit your stories now via social or:
Email: eyewitness@pulse.ng
Recommended articles
Here's everything to know about being a virgin on your wedding night
7 do's and don’ts of the Holy month of Ramadan
Top 5 sweetest celebrity mother-child relationships that stand out for us
International Women's Day: 5 Nigerian female celebrities championing women’s rights
Top 5 female directors in Nollywood
6 things that will break a Muslim's fast during Ramadan
5 benefits of fasting during Ramadan
5 reasons Easter was more fun when we were children
Dos and don’ts of supporting Muslims during Ramadan
ADVERTISEMENT